Mikrobiomik

Executive Summary

Mikrobiomik is a Spanish biotechnology company focused on developing microbiome-based therapies, with its lead product EUTEGRA (MBK-01) already authorized for recurrent Clostridioides difficile infection (CDI). Founded in 2016, the company leverages the human intestinal microbiota to target serious gastrointestinal and liver diseases. With an approved product in the market, Mikrobiomik is well-positioned to build a pipeline of innovative treatments. The company's expertise in manufacturing biological medicines and its proprietary platform offer potential for expansion into inflammatory bowel disease (IBD) and other conditions. As a private firm, Mikrobiomik is poised for growth through regulatory approvals, clinical data readouts, and strategic partnerships, though it faces competition from other microbiome players like Seres Therapeutics and Finch Therapeutics.

Upcoming Catalysts (preview)

• Q3 2026Regulatory approval of EUTEGRA in additional European markets85% success
• Q4 2026Phase 2 data readout for MBK-01 in inflammatory bowel disease (IBD)60% success
• Q2 2026Strategic partnership or licensing deal for pipeline candidates70% success